The bank's shares climbed as it beat analysts' expectations despite facing a commercial real estate charge of $700m in Hong Kong. Chairman Brendan Nelson is confident of growth in Asia this year.

Amid a structural shift towards Asia, Insilico Medicine's IPO in December was a significant moment for the exchange, while French biotech TheraVectys is understood to be considering a listing.

SC's operating profit grew 6% last year; Zurich Australia snaps up life insurer ClearView; Citi Vietnam appoints Thai Nguyet Minh as head of markets.

US president Donald Trump has issued 15% tariffs on every country exporting to the US after his so-called reciprocal tariffs were ruled illegal by the US Supreme Court.

Net profit at the Singapore bank fell 10% in Q4 amid rate headwinds, higher tax expenses and the absence of non-recurring gains; annual revenue in FY 2025 climbed to a record high of S$22.9bn.

A two-thirds supermajority in the Lower House will allow prime minister Sanae Takaichi to push through her tax cutting agenda.

The buoyancy in the sector is being driven by multiple factors, including regulatory shifts, policy support, and debt capital market activity in the city.

Amid regional market momentum, the global bank has a strong pipeline of Apac deals across ECM, DCM and M&A.